Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium Oxide for Acute Mild TBI in Adolescents
NCT03475693Phase 1Completed
- Sponsor
- Corewell Health
- Start
- Sep 2017
- Primary completion
- Nov 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of magnesium oxide in traumatic brain injury (TBI) (2 arms), sponsored by Corewell Health. Primary endpoint: Change in Post Concussion Severity Index at 120 hours. Started Sep 2017; status: completed.
02
Drugs
magnesium oxide
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT03475693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03475693.